Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Brenner Tumor 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × VTX-2337 × Clear all
NCT01836029 2019-10-29

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Celgene

Phase 2 Completed
195 enrolled 13 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01666444 2019-09-26

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Celgene

Phase 2 Completed
297 enrolled 15 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡